Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma.
Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma.
复制标题
DOI：
10.1111/cup.12364
复制
发表时间：
2014-09
影响因子：
1.7
通讯作者：
Thomas NE
中科院分区：
文献类型：
--
作者：
Pearlstein MV;Zedek DC;Ollila DW;Treece A;Gulley ML;Groben PA;Thomas NE
BRAF mutation status, and therefore eligibility for BRAF inhibitors, is currently determined by sequencing methods. We assessed the validity of VE1, a monoclonal antibody against the BRAF V600E mutant protein, in the detection of mutant BRAF V600E melanomas as classified by DNA pyrosequencing. The cases were 76 metastatic melanoma patients with only one known primary melanoma who had had BRAF codon 600 pyrosequencing of either their primary (n=19), metastatic (n=57) melanoma, or both (n=17). All melanomas (n=93) were immunostained with the BRAF VE1 antibody using a red detection system. The staining intensity of these specimens was scored from 0 – 3+ by a dermatopathologist. Scores of 0 and 1+ were considered as negative staining while scores of 2+ and 3+ were considered positive. The VE1 antibody demonstrated a sensitivity of 85% and a specificity of 100% as compared to DNA pyrosequencing results. There was 100% concordance between VE1 immunostaining of primary and metastatic melanomas from the same patient. V600K, V600Q, and V600R BRAF melanomas did not positively stain with VE1. This hospital-based study finds high sensitivity and specificity for the BRAF VE1 immunostain in comparison to pyrosequencing in detection of BRAF V600E in melanomas.
登录
查看更多内容
影响因子：
50.3
作者：
De Carvalho DD;Sharma S;You JS;Su SF;Taberlay PC;Kelly TK;Yang X;Liang G;Jones PA
通讯作者：
Jones PA
影响因子：
4.6
作者：
Marin, Cristi;Beauchet, Alain;Emile, Jean-Francois
通讯作者：
Emile, Jean-Francois
影响因子：
5.6
作者：
Busam, Klaus J.;Hedvat, Cyrus;Jungbluth, Achim A.
通讯作者：
Jungbluth, Achim A.
影响因子：
2.2
作者：
Edlundh-Rose, Esther;Egyhazi, Suzanne;Lundeberg, Joakim
通讯作者：
Lundeberg, Joakim
影响因子：
10.3
作者：
Schlaak, M.;Bajah, A.;Kurschat, P.
通讯作者：
Kurschat, P.